In a new study that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy.
“We’re using a cell as a reaction vessel and a disease-causing defect as a catalyst to synthesize a treatment in a diseased cell,” said TSRI Professor Matthew Disney. “Because the treatment is synthesized only in diseased cells, the compounds could provide highly specific therapeutics that only act when a disease is present. This means we can potentially treat a host of conditions in a very selective and precise manner in totally unprecedented ways.”
The promising research was published recently in the international chemistry journal Angewandte Chemie.
Targeting RNA Repeats
In general, small, low molecular weight compounds can pass the blood-brain barrier, while larger, higher weight compounds tend to be more potent. In the new study, however, small molecules became powerful inhibitors when they bound to targets in cells expressing an RNA defect, such as those found in myotonic dystrophy.
Myotonic dystrophy type 2, a relatively mild and uncommon form of the progressive muscle weakening disease, is caused by a type of RNA defect known as a “tetranucleotide repeat,” in which a series of four nucleotides is repeated more times than normal in an individual’s genetic code. In this case, a cytosine-cytosine-uracil-guanine (CCUG) repeat binds to the protein MBNL1, rendering it inactive and resulting in RNA splicing abnormalities that, in turn, results in the disease.
In the study, a pair of small molecule “modules” the scientists developed binds to adjacent parts of the defect in a living cell, bringing these groups close together. Under these conditions, the adjacent parts reach out to one another and, as Disney describes it, permanently hold hands. Once that connection is made, the small molecule binds tightly to the defect, potently reversing disease defects on a molecular level.
“When these compounds assemble in the cell, they are 1,000 times more potent than the small molecule itself and 100 times more potent than our most active lead compound,” said Research Associate Suzanne Rzuczek, the first author of the study. “This is the first time this has been validated in live cells.”
The Latest on: Specific therapeutics
via Google News
The Latest on: Specific therapeutics
- CymaBay Therapeutics, Inc.'s (CBAY) CEO Sujal Shah on Q2 2020 Results - Earnings Call Transcripton August 10, 2020 at 8:33 pm
Q2 2020 Results Earnings Conference Call August 10, 2020, 4:30 PM ET Company Participants Dan Menold - Vice President, Finance Sujal Shah - Chief Executive Officer Dr.
- Plus Therapeutics, Inc.(PSTV) CEO Marc Hedrick on Q2 2020 Results - Earnings Call Transcripton August 10, 2020 at 7:21 pm
Q2 2020 Earnings Conference Call August 10, 2020 05:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Conference Call Participants Robert LeBoyer - Ladenburg Thalmann Ed ...
- Amicus Therapeutics Inc (FOLD) Q2 2020 Earnings Call Transcripton August 10, 2020 at 4:11 pm
Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics' Second Quarter 2020 Financial Results Conference Call and Webcast. [Operator Instructions] I would now like to turn the ...
- Sage Therapeutics Inc (SAGE) Q2 2020 Earnings Call Transcripton August 10, 2020 at 2:44 pm
Q2 2020 Earnings Call Aug 10, 2020, 8:30 a.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Parti ...
- Instead of Looking at the 'Big Picture,' Zero in on Specific Stockson August 10, 2020 at 2:03 pm
When the market has a run like this, there is always the temptation to feel like we are 'due' for a correction, but that's not a strategy.
- Axsome Therapeutics, Inc. (AXSM) Q2 2020 Earnings Call Transcripton August 10, 2020 at 9:00 am
Q2 2020 Earnings Call Aug 10, 2020, 8:00 a.m. ET Operator Good morning and welcome to the Axsome Therapeutics Conference Call. [Operator Instructions] Now, I'd like to turn the conference over to your ...
- Global Psoriatic Arthritis Therapeutics Market 2020 With COVID-19 Update, Industry Segmentation, CAGR Status, Leading Trends, and Forecast To 2026on August 10, 2020 at 5:20 am
Increasing binge eating and consumption of junk foods, neglect towards regular exercise, rising levels of stress, are key market drivers. The report discusses more information about these subjects, ...
- LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updateson August 10, 2020 at 3:48 am
FDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric PatientsLEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) ...
- LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patientson August 10, 2020 at 3:35 am
LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform – – Enrollment to Start with Patients as Young as 3 Years Old, De-escalating Down ...
- NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directorson August 10, 2020 at 12:00 am
NBE-Therapeutics, the Swiss-based company developing best-in- class cancer therapies based on its proprietary, ...
via Bing News